肉腫治療薬の世界市場2019-2023

◆英語タイトル:Global Sarcoma Therapeutics Market 2019-2023
◆商品コード:IRTNTR30495
◆発行会社(リサーチ会社):Technavio
◆発行日:2018年12月14日
◆ページ数:114
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥267,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥321,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥428,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、肉腫治療薬の世界市場について調査・分析し、市場概要、市場環境、肉腫治療薬市場規模、種類別(軟部組織肉腫、骨肉種)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・肉腫治療薬の世界市場概要
・肉腫治療薬の世界市場環境
・肉腫治療薬の世界市場動向
・肉腫治療薬の世界市場規模
・肉腫治療薬の世界市場:業界構造分析
・肉腫治療薬の世界市場:種類別(軟部組織肉腫、骨肉種)
・肉腫治療薬の世界市場:地域別市場規模・分析
・肉腫治療薬の北米市場規模・予測
・肉腫治療薬のヨーロッパ・中東・アフリカ市場規模・予測
・肉腫治療薬のアジア太平洋市場規模・予測
・肉腫治療薬の主要国分析
・肉腫治療薬の世界市場:意思決定フレームワーク
・肉腫治療薬の世界市場:成長要因、課題
・肉腫治療薬の世界市場:競争環境
・肉腫治療薬の世界市場:関連企業情報(ベンダー分析)

主な分析対象企業は、Bayer、Eisai、Eli Lilly、Johnson & Johnson、Novartisなどです。
【レポートの概要】

About this market
The advent of regenerative medicine to drive growth in the market. One of the most advanced and extensively researched treatment methods is regenerative medicines, including gene therapy. In gene therapy, the mutated gene is taken from the patient and is modified genetically in laboratory and administered back into the patient. Technavio’s analysts have predicted that the sarcoma therapeutics market will register a CAGR of more than 8% by 2023.
Market Overview
Launch of novel drugs
The market is currently dominated by the sales of GLEEVEC for the treatment of sarcomas. The launch of novel drugs is expected to be one of the major growth drivers in the market.
High treatment costs
The cost of therapeutics is usually high as most of the drugs that are currently approved in the market are large molecules. These drugs are expensive due to the complex manufacturing process of biologicals and high R&D costs.
For the detailed list of factors that will drive and challenge the growth of the sarcoma therapeutics market during the 2019-2023, view our report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including Bayer and Eisai the competitive environment is quite intense. Factors such as the advent of regenerative medicine and the launch of novel drugs, will provide considerable growth opportunities to sarcoma therapeutics manufactures. Bayer, Eisai, Eli Lilly, Johnson & Johnson, and Novartis are some of the major companies covered in this report.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: PIPELINE
PART 07: MARKET SEGMENTATION BY TYPE
• Market segmentation by type
• Comparison by type
• Soft tissue sarcoma – Market size and forecast 2018-2023
• Osteosarcoma – Market size and forecast 2018-2023
• Market opportunity by type
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Americas – Market size and forecast 2018-2023
• EMEA – Market size and forecast 2018-2023
• APAC – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 12: MARKET TRENDS
PART 13: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 14: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Bayer
• Eisai
• Eli Lilly
• Johnson & Johnson
• Novartis
PART 15: APPENDIX
• Research methodology
• List of abbreviations
PART 16: EXPLORE TECHNAVIO


Exhibit 01: Global oncology therapeutics market
Exhibit 02: Segments of global oncology therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition – Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition – Five forces 2018
Exhibit 17: Global sarcoma therapeutics market pipeline: Overview
Exhibit 18: Type – Market share 2018-2023 (%)
Exhibit 19: Comparison by type
Exhibit 20: Soft tissue sarcoma – Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Soft tissue sarcoma – Year-over-year growth 2019-2023 (%)
Exhibit 22: Osteosarcoma – Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Osteosarcoma – Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by type
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: Americas – Market size and forecast 2018-2023 ($ millions)
Exhibit 29: Americas – Year-over-year growth 2019-2023 (%)
Exhibit 30: EMEA – Market size and forecast 2018-2023 ($ millions)
Exhibit 31: EMEA – Year-over-year growth 2019-2023 (%)
Exhibit 32: APAC – Market size and forecast 2018-2023 ($ millions)
Exhibit 33: APAC – Year-over-year growth 2019-2023 (%)
Exhibit 34: Key leading countries
Exhibit 35: Market opportunity
Exhibit 36: Impact of drivers and challenges
Exhibit 37: Vendor landscape
Exhibit 38: Landscape disruption
Exhibit 39: Vendors covered
Exhibit 40: Vendor classification
Exhibit 41: Market positioning of vendors
Exhibit 42: Bayer – Vendor overview
Exhibit 43: Bayer – Business segments
Exhibit 44: Bayer – Organizational developments
Exhibit 45: Bayer – Geographic focus
Exhibit 46: Bayer – Segment focus
Exhibit 47: Bayer – Key offerings
Exhibit 48: Bayer – Key customers
Exhibit 49: Eisai – Vendor overview
Exhibit 50: Eisai – Business segments
Exhibit 51: Eisai – Organizational developments
Exhibit 52: Eisai – Geographic focus
Exhibit 53: Eisai – Segment focus
Exhibit 54: Eisai – Key offerings
Exhibit 55: Eisai – Key customers
Exhibit 56: Eli Lilly – Vendor overview
Exhibit 57: Eli Lilly – Business segments
Exhibit 58: Eli Lilly – Organizational developments
Exhibit 59: Eli Lilly – Geographic focus
Exhibit 60: Eli Lilly – Segment focus
Exhibit 61: Eli Lilly – Key offerings
Exhibit 62: Eli Lilly – Key customers
Exhibit 63: Johnson & Johnson – Vendor overview
Exhibit 64: Johnson & Johnson – Business segments
Exhibit 65: Johnson & Johnson – Organizational developments
Exhibit 66: Johnson & Johnson – Geographic focus
Exhibit 67: Johnson & Johnson – Segment focus
Exhibit 68: Johnson & Johnson – Key offerings
Exhibit 69: Johnson & Johnson – Key customers
Exhibit 70: Novartis – Vendor overview
Exhibit 71: Novartis – Business segments
Exhibit 72: Novartis – Organizational developments
Exhibit 73: Novartis – Geographic focus
Exhibit 74: Novartis – Segment focus
Exhibit 75: Novartis – Key offerings
Exhibit 76: Novartis – Key customers




【掲載企業】

Bayer、Eisai、Eli Lilly、Johnson & Johnson、Novartis

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[肉腫治療薬の世界市場2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆